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Mast cells are derived from myeloid progenitor 
cells and widely distributed throughout vascu-
larized tissues. They participate in innate and 
adaptive immune defenses against bacteria and 
parasites and play a key role in IgE-mediated 
allergic diseases such as atopy and asthma, 
which are responsible for increasing global 
health problems (1). Moreover, mast cells con-
tribute to autoimmunity and are involved in 
pathological tissue remodeling processes that 
are associated with chronic infl  ammation. All 
these biological and pathological functions are 
triggered by mast cell–derived proinfl  amma-
tory mediators such as histamine, arachidonic 
acid metabolites, and cytokines, which are re-
leased upon mast cell activation.
The major stimulus for mast cell activation 
is the aggregation of the high-affi   nity receptor 
for IgE, FcεRI (2, 3). Cross-linking of FcεRI-
bound IgE with multivalent antigen or aller-
gen triggers a series of biochemical events that 
culminate in mast cell eff  ector function. Sig-
naling is initiated through the phosphorylation 
of immunoreceptor tyrosine-based activation 
motifs in the tails of the FcεRI β and γ sub-
units by Src family protein tyrosine kinases (2). 
The tyrosine-phosphorylated immunoreceptor 
tyrosine-based activation motifs recruit the ki-
nase Syk, which, together with the activated 
receptor-proximal Src protein tyrosine kinases, 
mediates phosphorylation and consequent re-
organization of adaptor and scaff  olding proteins 
at the activated FcεRI complex. Collectively, 
early signaling induces the activation of down-
stream enzymes such as phosphatidylinositol 
3–kinase and phospholipase C, the generation 
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Mast cells are pivotal effector cells in IgE-mediated allergic infl  ammatory diseases. Central 
for mast cell activation are signals from the IgE receptor Fc𝗆RI, which induce cell degranu-
lation with the release of preformed mediators and de novo synthesis of proinfl  ammatory 
leukotrienes and cytokines. How these individual mast cell responses are differentially 
controlled is still unresolved. We identify B cell lymphoma 10 (Bcl10) and mucosa-
  associated lymphoid tissue 1 (Malt1) as novel key regulators of mast cell signaling. Mice 
defi  cient for either protein display severely impaired IgE-dependent late phase anaphylactic 
reactions. Mast cells from these animals neither activate nuclear factor 𝗋B (NF-𝗋B) nor 
produce tumor necrosis factor 𝗂 or interleukin 6 upon Fc𝗆RI ligation even though proximal 
signaling, degranulation, and leukotriene secretion are normal. Thus, Bcl10 and Malt1 are 
essential positive mediators of Fc𝗆RI-dependent mast cell activation that selectively 
  uncouple NF-𝗋B–induced proinfl  ammatory cytokine production from degranulation and 
leukotriene synthesis.
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of second messengers (e.g., inositol-1,4,5-triphosphate, 1,2-
diacylglycerol, and free calcium), and activation of protein 
kinase C (PKC) isoforms.
Ultimately, FcεRI aggregation activates several down-
stream pathways that initiate the allergic infl  ammatory pro-
cess by eliciting mast cell degranulation with a rapid release of 
preformed vasoactive amines such as histamine and serotonin 
and by triggering the de novo synthesis of proinfl  ammatory 
arachidonic acid metabolites and potent cytokines like TNF-
α or IL-6 (1). In addition, signals from the FcεRI activate 
genetic survival programs that block cell death after IgE stim-
ulation (4, 5). Crucial for immediate-type allergic reactions is 
the instant degranulation, whereas mast cell–mediated late 
phase reactions and IgE-induced chronic allergic infl  amma-
tory processes are mainly dependent on the production of 
cytokines and the initiation of leukocyte eff  ector cascades 
(1, 6). Major questions in mast cell biology are how early sig-
naling events after FcεRI aggregation are integrated and how 
selected mast cell responses—such as the immediate degranu-
lation or the delayed cytokine production—are individually 
controlled, because the identifi  cation of molecules that regu-
late specifi   c mast cell eff   ector functions selectively would 
provide novel targets for rational therapies of mast cell–medi-
ated diseases (3).
NF-κB is a master transcription factor that controls the 
expression of proinfl  ammatory gene products in cells of many 
diff   erent lineages (7). The predominant NF-κB dimer in 
many cell types, including mast cells, is a p50/RelA hetero-
dimer (7, 8). The activity of NF-κB is tightly controlled by 
inhibitor of κB (IκB) proteins that can bind to NF-κB dimers 
and retain them in an inactive state in the cytoplasm. NF-κB 
can be activated through either the canonical or the alterna-
tive pathway (7). The canonical pathway is responsible for 
the activation of p50/RelA dimers and involves the activa-
tion of the multisubunit IκB kinase (IKK) that phosphory-
lates IκB proteins on conserved serine residues to target them 
to ubiquitin-dependent degradation. This process frees NF-
κB and allows its translocation into the nucleus and transacti-
vation of target genes. Many of the proinfl  ammatory cytokine 
genes that are expressed in activated mast cells are regulated 
by NF-κB (7–14). In particular, the production of TNF-α 
and IL-6 in response to FcεRI ligation is strictly dependent 
on IKK and NF-κB activity (10, 14). Both cytokines play 
key roles in mast cell–mediated infl  ammatory responses. Yet, 
the signaling intermediates that connect FcεRI-proximal 
events to IKK activation are unknown.
Recently, the caspase recruitment domain protein B cell 
lymphoma 10 (Bcl10) and the paracaspase mucosa-associated 
lymphoid tissue 1 (Malt1) were identifi  ed as key regulators of 
T cell and B cell antigen receptor signaling (15). Bcl10 and 
Malt1 can directly bind to each other, and the two proteins 
cooperate in the assembly of a cellular complex that can me-
diate signal-specifi  c activation of IKK. Both Bcl10 and Malt1 
additionally regulate the c-Jun NH2-terminal kinase (Jnk) 
and p38 mitogen-activated protein (MAP) kinase pathways 
in lymphocytes, and Bcl10 also has a Malt1-independent role 
during neurodevelopment (16–20). Immunological functions 
of Bcl10 and Malt1 in nonlymphoid cells are still largely un-
defi  ned, and it is as of yet unknown whether they play any 
role in mast cells.
In this paper, we show that Bcl10 and Malt1 are essential 
for normal mast cell function in vivo and in vitro. Although 
mice defi  cient for either molecule exhibit normal numbers of 
skin mast cells and regular IgE-mediated immediate phase 
anaphylactic reactions, late phase anaphylactic reactions are 
severely blunted in these animals. In vitro bone marrow–de-
rived mast cells from Bcl10- or Malt1-defi  cient mice neither 
produce TNF-α nor IL-6 in response to FcεRI stimulation, 
whereas the capacity to produce leukotrienes and degranula-
tion is normal. On a molecular level, we fi  nd that FcεRI-
proximal signaling (the activation of the MAP kinases 
extracellular signal–regulated kinase [Erk], Jnk, and p38) and 
the activation of Akt are intact in Bcl10- or Malt1-defi  cient 
mast cells. However, NF-κB cannot be activated in response 
to FcεRI aggregation. Thus, we identify Bcl10 and Malt1 as 
crucial positive regulators of FcεRI-dependent NF-κB acti-
vation that selectively uncouple proinfl  ammatory cytokine 
production from degranulation and lipid mediator synthesis.
RESULTS
Mast cell development is not affected by Bcl10 
or Malt1 defi  ciency
To study potential roles for Bcl10 and Malt1 in mast cells, we 
fi  rst assessed the eff  ects of genetic Bcl10 or Malt1 disruptions 
in mice on several aspects of mast cell development in vivo 
and in vitro (Fig. 1). Mast cells in the skin of WT, Bcl10-
  defi  cient (Bcl10−/−), and Malt1-defi  cient (Malt1−/−) mice 
were comparable in their morphology and anatomical distri-
bution (Fig. 1 A). The frequencies of these cells in the dermis 
of the ear, neck, and groin were similar in all three genotypes 
as determined after toluidine blue staining (Fig. 1 B).
In vitro culture of WT, Bcl10−/−, and Malt1−/− bone 
marrow cell suspensions in the presence of IL-3 and stem cell 
factor (SCF) revealed highly pure mast cell populations in all 
three genotypes (bone marrow–derived mast cells [BMMCs]). 
These cells were indistinguishable in morphology when 
stained with toluidine blue or with alcian blue (unpublished 
data). The growth rate and total cell numbers in these cul-
tures, as well as the frequency of BMMCs (constantly >95%) 
as revealed by fl  ow cytometric analysis of the surface expres-
sion of c-kit and FcεRI, were also equal (Fig. 1 C). Impor-
tantly, the FcεRI expression level was not infl  uenced  by 
either the Bcl10 or Malt1 disruption. Western blot analysis 
demonstrated that WT mast cells express both Bcl10 and 
Malt1 (Fig. 1 D). As expected, Bcl10−/− mast cells do not 
produce the Bcl10 protein, whereas Malt1−/− mast cells do 
not contain the Malt1 protein. Collectively, these fi  ndings 
demonstrate that, although Bcl10 and Malt1 are expressed in 
normal mast cells, their absence aff  ects neither skin mast cell 
development in vivo nor BMMC diff  erentiation in vitro. 
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Malt1−/− mast cells and the Malt1 protein concentration is 
smaller in Bcl10−/− BMMCs compared with the WT, sug-
gesting that cellular levels of each of the two binding partners 
depend on the presence of the other.
Bcl10 and Malt1 are required for normal mast 
cell function in vivo
To test whether Bcl10 or Malt1 play a functional role in mast 
cells in vivo, we performed two types of FcεRI-mediated 
passive cutaneous anaphylaxis (PCA) experiments (21, 22). 
We addressed the immediate and the late phase PCA re-
sponses separately (Fig. 2).
For early phase PCA reactions, mice were primed by in-
tradermal injection of monoclonal anti-dinitrophenyl (anti-
DNP) IgE antibody into the ear. 24 h later, the animals were 
i.v. coinjected with Evans blue dye and the antigen DNP 
coupled to HSA (DNP–HSA). The extravasation of Evans 
blue dye during the fi  rst hour of the PCA reaction is mainly 
dependent on the degranulation of activated mast cells with 
rapid histamine and serotonin release resulting in locally in-
creased blood vessel permeability (21). The Evans blue dye 
extravasation was monitored by inspection and quantifi  ed 
60 min after antigen challenge (Fig. 2, A and B). Neither the 
extravasation kinetics nor the total amount of Evans blue dye 
in the ear were substantially diff  erent in the three genotypes, 
indicating that the mast cell–mediated immediate phase PCA 
reaction does not require Bcl10 or Malt1.
We next examined the late phase PCA response that is 
promoted by mast cell–derived proinfl  ammatory cytokines 
(1, 23, 24). Mice were sensitized i.v. with anti-DNP IgE an-
tibody. 24 h later, the hapten dinitrofl  uorobenzene (DNFB; 
0.2% wt/vol) was epicutaneously applied to both sides of the 
ears. Although WT mice exhibited the anticipated promi-
nent edema as early as 6 h and reached a maximum 24 h after 
antigen stimulation, both Bcl10−/− and Malt1−/− mice 
showed only a minor response (Fig. 2 C). Even 24 and 48 h 
after antigen challenge, the increase in ear thickness in the 
mutant animals reached <20% of that observed in WT mice. 
Therefore, we conclude that both Bcl10 and Malt1 are es-
sentially required for regular IgE-dependent late phase PCA 
reactions in vivo.
Bcl10 and Malt1 differentially regulate Fc𝗆RI-mediated 
degranulation, lipid mediator secretion, 
and cytokine production
To provide a basis for the defective PCA reactions in Bcl10- 
and Malt1-defi  cient mice, we examined the capacities of 
Bcl10−/−, Malt1−/−, and WT mast cells to degranulate, syn-
thesize, and secrete lipid mediators and to produce cytokines 
(Fig. 3 and see Fig. 4). These and all subsequent analyses were 
performed on BMMCs in vitro.
WT, Bcl10−/−, and Malt1−/− BMMCs were loaded with 
antigen-specifi   c IgE and subsequently activated by FcεRI 
cross-linking with increasing doses of multivalent antigen to 
induce cell degranulation (Fig. 3 A). Mast cells release the 
enzyme β-hexosaminidase from intracellular granules whose 
activity in the culture supernatant can be quantifi  ed to deter-
mine the effi   ciency of mast cell degranulation (25). Consis-
tent with the normal Evans blue dye extravasation during the 
immediate phase PCA reaction in vivo, mast cells derived 
from Bcl10- or Malt1-defi  cient mice released similar amounts 
of β-hexosaminidase as WT BMMCs in response to FcεRI 
ligation. We also stimulated cells with PMA together with 
the calcium ionophore ionomycin (Iono). These pharmaco-
logical agents bypass FcεRI-proximal signaling events and 
stimulate cells directly by mobilizing free calcium ions and 
Figure 1.  Mast cell development in the absence of Bcl10 or Malt1. 
(A and B) Skin biopsies from WT, Bcl10−/−, and Malt1−/− mice. (A) Repre-
sentative areas from the ear skin show the presence of toluidine blue–
positive mast cells in all three genotypes (arrowheads) at 20×. Insets at 
100× show the boxed mast cells from each section. Bars: (full images) 
10 μm; (insets) 2 μm. (B) Mast cell frequencies in skin sections from the 
ear, neck, and groin (n = 3 mice/genotype). There was no important dif-
ference among the three genotypes. Data are means ± SEM. (C) Flow 
cytometric analysis of BMMCs from WT, Bcl10−/−, and Malt1−/− mice. 
Percentages of FcεRI and c-kit double-positive mast cells are indicated. 
Results are representative of fi  ve different experiments. (D) Bcl10 and 
Malt1 expression levels in BMMCs. Western blots of WT, Bcl10−/−, and 
Malt1−/− BMMCs with antibodies against Bcl10, Malt1, and β-actin. 
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activating PKC enzymes. Again, no substantial diff  erences in 
β-hexosaminidase activity were detected in the supernatants 
of BMMCs of the three genotypes (Fig. 3 A).
Furthermore, we investigated the production of proin-
fl  ammatory lipid mediators in WT, Bcl10−/−, and Malt1−/− 
BMMCs in response to FcεRI ligation using an enzyme-
linked immunoassay (Fig. 3 B). Mast cells of the three geno-
types produced equal amounts of the leukotrienes C4, D4, 
and E4 (LTC4, LTD4, and LTE4). BMMC activation with 
PMA/Iono also induces robust leukotriene production. 
Again, no diff  erences were found between WT, Bcl10−/−, 
and Malt1−/− BMMCs (Fig. 3 B). Collectively, these fi  rst sets 
of in vitro experiments show that the signaling proteins Bcl10 
and Malt1 are dispensable for mast cell degranulation or leu-
kotriene synthesis in response to FcεRI ligation or PMA/
Iono treatment.
It is known that the late phase PCA response in vivo is at 
least in part induced by proinfl  ammatory cytokines, in partic-
ular TNF-α, released from activated mast cells (1, 23, 24). 
Therefore, we were especially interested in measuring the 
transcriptional induction, production, and release of cyto-
kines by Bcl10−/− and Malt1−/− mast cells in response to 
FcεRI stimulation in vitro. To this end, we fi  rst performed 
time course experiments and analyzed the concentrations of 
TNF-α and IL-6 in the supernatant of stimulated cells by 
ELISA. WT mast cells produced both mediators readily (Fig. 
4 A). The maximal concentrations were detected after 2 h 
of   stimulation. In sharp contrast, Bcl10−/− and Malt1−/− 
BMMCs produced only minute amounts of TNF-α or IL-6 
even at later time points. To further characterize the defects 
in TNF-α and IL-6 production in Bcl10- and Malt1-defi  -
cient BMMCs, we analyzed cytokine mRNA levels before 
and 30 min after FcεRI ligation using semiquantitative RT-
PCR. Unstimulated and stimulated populations of all three 
cell lines contained equal amounts of β-actin transcripts, indi-
cating appropriate normalization (Fig. 4 B). In WT BMMCs, 
both TNF-α and IL-6 mRNA levels increased substantially 
upon FcεRI stimulation. However, in the absence of Bcl10 
or Malt1 the induction of these cytokine transcripts was ei-
ther absent or largely reduced compared with the WT. Thus, 
Bcl10 and Malt1 are critically required for FcεRI-mediated 
TNF-α and IL-6 gene transcription and subsequent protein 
production. These results indicate that the defective PCA re-
actions observed in Bcl10- or Malt1-defi  cient mice in vivo 
might refl  ect the essential requirements for the two signaling 
proteins for FcεRI-mediated cytokine production.
Bcl10 and Malt1 are dispensable for IgE-induced mast 
cell survival
In lymphocytes, Bcl10 and Malt1 are not only vital for cell 
activation but also involved in the regulation of cell survival 
(15). Because recent studies demonstrated a role for FcεRI-
derived signals in the control of mast cell survival (4, 5), we 
also studied the contributions of Bcl10 and Malt1 to this 
Figure 2.  Normal immediate but defective late phase PCA in 
Bcl10−/− and Malt1−/− mice. (A and B) Immediate phase PCA reactions. 
Mice were passively sensitized by intradermal injection of anti-DNP IgE 
into the left ear. The right ear was injected with PBS. Subsequently, mice 
were challenged by i.v. injection of antigen in PBS/Evans blue. (A) Ears 
from WT, Bcl10−/−, and Malt1−/− mice 1 h after antigen challenge. (B) The 
IgE-mediated Evans blue extravasation was calculated as the difference in 
the amount of extravasated dye in the IgE-sensitized and the nonsensi-
tized control ears. Differences between the three geno-types were not 
statistically signifi  cant ( P ≥ 0.05). (C) Late phase PCA reactions. WT, 
Bcl10−/−, and Malt1−/− mice were passively sensitized by i.v. injection of 
anti-DNP IgE. 24 h later, they were challenged by epicuta-neous applica-
tion of DNFB to both ears, and ear thickness was measured over time. 
The increase in ear thickness was calculated as described in Material and 
methods. Results are representative of three independent experiments. 
Data are presented as means ± SEM. * and **, P ≤ 0.05 and P ≤ 0.02 
between WT and Bcl10−/− or WT and Malt−/− mice, respectively.JEM VOL. 203, February 20, 2006  341
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pathway (Fig. 5). BMMCs of WT, Bcl10−/−, and Malt1−/− 
mice were incubated for 4 d in media with low concentra-
tions of FCS without IL-3 and SCF. This growth factor 
withdrawal induced apoptotic death of WT, Bcl10−/−, and 
Malt1−/− BMMCs. The frequency of apoptotic cells was in-
dependent of the presence of Bcl10 or Malt1 as determined 
by fl  ow cytometry after annexin V/propidium iodide stain-
ing. (Fig. 5 A). Stimulation of cells with IgE alone or in com-
bination with antigen (unpublished data) rescued cell death 
and up-regulated the expression of the prosurvival protein 
Bcl-XL in mast cells of all three genotypes similarly (Fig. 5 B). 
We thus conclude that Bcl10 and Malt1 are not essential for 
the FcεRI-controlled survival pathway.
Bcl10 and Malt1 are essential regulators 
of Fc𝗆RI-controlled NF-𝗋B activation
To defi   ne the molecular mechanisms responsible for the 
  defective cytokine gene expression in Bcl10- and Malt1-
  defi   cient mast cells, we analyzed the signaling pathways 
downstream of FcεRI stimulation (Fig. 6 and see Fig. 7).
Ligation of IgE-occupied FcεRI molecules with antigen 
results in the rapid activation of receptor-proximal tyrosine 
kinases, which is a prerequisite for all mast cell eff  ector func-
tions (2). Consistent with the normal degranulation and lipid 
mediator synthesis in Bcl10−/− and Malt1−/− mast cells, re-
ceptor-proximal signaling does not involve Bcl10 or Malt1 
because the tyrosine phosphorylation patterns induced by 
FcεRI stimulation did not diff   er in kinetics or intensity 
among BMMCs of the three genotypes (Fig. 6 A).
Figure 3.  Normal degranulation and leukotriene synthesis in 
Bcl10−/− and Malt1−/− BMMCs. (A) Regular degranulation of Bcl10−/− 
and Malt1−/− mast cells. BMMCs from WT, Bcl10−/−, and Malt−/− mice 
were loaded with anti-DNP IgE and subsequently stimulated for 30 min 
with the indicated concentrations of DNP–HSA. Alternatively, BMMCs 
were left unsensitized and stimulated with PMA/Iono (100 nM each) for 
30 min. The extent of degranulation was determined by measuring the 
activity of the granular enzyme β-hexosaminidase in supernatants and 
cell lysates and calculated as described in Material and methods. Data are   
means ± SEM from triplicate samples and are representative of four in-
dependent experiments. (B) Regular leukotriene synthesis in Bcl10−/− and 
Malt1−/− mast cells. Anti-DNP IgE-sensitized BMMCs from all three geno-
types were stimulated with DNP–HSA at the indicated concentrations, or 
BMMCs were left unsensitized and stimulated with PMA/Iono (100 nM 
each). 60 min later, the supernatants of the stimulated cells were col-
lected and assayed for the concentrations of LTC4, LTD4, and LTE4. Data 
are means ± SEM from triplicate samples and representative of four 
 independent  experiments.
Figure 4.  Defective cytokine production in Bcl10−/− and Malt1−/− 
BMMCs. (A) Impaired cytokine secretion in Bcl10−/− and Malt1−/− mast 
cells. WT, Bcl10−/−, and Malt1−/− BMMCs were loaded with anti-DNP IgE 
and stimulated with DNP–HSA for the indicated intervals. Supernatants 
were collected, and TNF-α and IL-6 protein concentrations were deter-
mined by ELISA. Data are means ± SEM from triplicate samples and rep-
resentative of at least fi  ve independent experiments. * and **, P ≤ 0.05 
and P ≤ 0.01 between WT and Bcl10−/− or WT and Malt1−/− BMMCs, 
  respectively. (B) Defective expression of cytokine mRNAs in Bcl10−/− and 
Malt1−/− mast cells. BMMCs from WT, Bcl10−/−, and Malt1−/− mice were 
stimulated for 30 min as in A. RNA was purifi  ed, and TNF-α, IL-6, and 
β-actin mRNAs were detected by semiquantitative RT-PCR using specifi  c 
primers. Data are representative of three independent experiments.342   REGULATION OF FCεRI SIGNALING BY BCL10 AND MALT1 | Klemm et al.
FcεRI-proximal signaling activates the Erk, Jnk, and 
p38 pathways, as well as the phosphatidylinositol 3–kinase 
pathway that results in the activation of the serine kinase 
Akt. These cascades regulate both cytokine production and 
generation of arachidonic acid metabolites upon FcεRI li-
gation (1, 2). Bcl10 and Malt1 have been implicated in the 
regulation of Jnk and p38 signaling in lymphocytes (18, 19). 
However, using immunoblotting with activation state–spe-
cifi  c phosphoantibodies against Jnk, p38, the p42 and p44 
MAP kinases Erk1 and Erk2, or Akt, we could not detect 
diff  erences in the FcεRI-induced activation of any of these 
pathways among WT, Bcl10−/−, and Malt1−/− mast cells 
(Fig. 6 B). We additionally activated the cells with PMA/
Iono and again detected similar activation for Jnk, p38, 
Erk1, Erk2, and Akt in the presence or absence of either 
Bcl10 or Malt1 (Fig. 6 C).
As earlier mentioned, the expression of TNF-α and IL-
6 critically depends on the activation of NF-κB. Based on 
known functions of Bcl10 and Malt1 in lymphocytes and 
their newly discovered requirement in mast cells, we rea-
soned that the two proteins might be involved in FcεRI-
mediated NF-κB activation. To test this hypothesis, we 
analyzed IκB-α phosphorylation and its subsequent degra-
dation in FcεRI-stimulated BMMCs of the three geno-
types. FcεRI signaling in WT cells induced rapid IκB-α 
phosphorylation and, consequently, its degradation (Fig. 
7 A). In contrast, signaling to IκB-α was completely abol-
ished in Bcl10−/− or in Malt1−/− mast cells. Direct PKC 
activation via PMA/Iono stimulation also resulted in IκB-α 
phosphorylation and degradation only in the WT cells but 
not in BMMCs defi  cient for either Bcl10 or Malt1, indi-
cating a requirement for Bcl10 and Malt1 downstream of 
PKC activation.
To directly investigate NF-κB nuclear translocation and 
DNA binding, we performed gel shift assays with nuclear ex-
tracts from stimulated mast cells. Consistent with the marked 
impairment of IκB-α phosphorylation and degradation in 
Bcl10−/− and Malt1−/− BMMCs, NF-κB was only activated 
in WT mast cells but not in those defi  cient for Bcl10 or Malt1 
(Fig. 7 B). Thus, Bcl10 and Malt1 are both essential to spe-
cifi  cally couple FcεRI and PKC signaling to the activation of 
the NF-κB pathway in mast cells.
DISCUSSION
In this paper, we have demonstrated on a genetic basis that 
Bcl10 and Malt1 are essential and nonredundant positive reg-
ulators of mast cell activation and eff  ector function. Although 
mast cells seem to diff  erentiate and survive normally in the 
absence of either Bcl10 or Malt1, both proteins are critically 
required for NF-κB activation induced by the high-affi   nity 
IgE receptor FcεRI. Bcl10- or Malt1-defi  cient mast cells do 
not produce the NF-κB–regulated proinfl  ammatory  cyto-
kines TNF-α and IL-6 and, consistently, late phase PCA re-
actions are severely impaired in Bcl10- or Malt1-defi  cient 
mice in vivo.
Activation of mast cells through the FcεRI initiates a 
  cascade of events that lead to degranulation, production of 
lipid mediators such as leukotrienes, and transcriptional up-
regulation and release of proinfl  ammatory cytokines such as 
TNF-α or IL-6. These all represent normal mast cell func-
tions that, depending on the context, may be benefi  cial or 
harmful in the setting of innate or allergic immune responses. 
Bcl10 and Malt1 are not involved in FcεRI-proximal signal-
ing events that are known to lead to the activation of PKC 
enzymes (2). The PKC family consists of at least 10 serine/
threonine kinases, and previous studies have indicated that 
PKC activation is involved in all aspects of mast cell eff  ector 
functions (26). Although comprehensive studies of the indi-
vidual roles of all PKC isoforms in mast cell biology are 
  missing, chemical or genetic inhibition of the PMA- and cal-
cium-sensitive conventional isoforms PKCα and PKCβ 
identifi  ed these kinases as essential inducers of degranulation 
and cytokine and leukotriene production (27–29). The 
PMA-sensitive but calcium-insensitive isoform PKCδ is in-
volved in the activation of leukotriene synthesis (30) and can 
simultaneously function as a negative regulator of antigen-
induced degranulation (31).
Figure 5.  Regular IgE-induced survival signaling in the absence of 
Bcl10 or Malt1. (A) BMMCs from all three genotypes were deprived of 
the mast cell survival cytokines IL-3 and SCF and cultured in media with 
low concentrations of FCS (1%) with or without 5 μg/ml anti-DNP IgE 
mAb. 48 and 96 h later, apoptotic cell death was determined by fl  ow 
  cytometry after annexin V/propidium iodide staining. The percentages of 
viable mast cells are shown. Data are means ± SEM from triplicate sam-
ples and are representative of four independent experiments. No impor-
tant differences were detected among the three genotypes. (B) BMMCs 
were cultured as in A and left unstimulated or stimulated for 24 h with 
5 μg/ml anti-DNP IgE. Total cell lysates were resolved by SDS-PAGE and 
immunoblotted with anti–Bcl-XL antibody and, after stripping, reprobed 
with anti–β-actin antibody to control for equal loading.JEM VOL. 203, February 20, 2006  343
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In this paper, we show that FcεRI- and PMA/Iono-in-
duced IκB-α phosphorylation, degradation, and NF-κB ac-
tivation are completely abolished in Bcl10- or Malt1-defi  cient 
mast cells. These results reveal an essential requirement for 
Bcl10–Malt1 signaling downstream of the FcεRI and down-
stream of all PMA-responsive PKCs in mast cells. Impor-
tantly, however, FcεRI- or PMA/Iono-induced activation 
of the Jnk, p38, Erk, and Akt pathways are intact in Bcl10−/− 
and Malt1−/− mast cells, indicating that the Bcl10–Malt1 
complex does not aff   ect all PKC downstream pathways. 
Consistent with the regular activation of selected FcεRI or 
PKC eff  ector signals, we observed normal mast cell survival, 
degranulation, and leukotriene production in the absence of 
Bcl10 or Malt1. The observation that TNF-α and IL-6 
transcription and protein production are severely impaired 
in Bcl10- or Malt1-  defi  cient mast cells is in agreement with 
our fi  ndings that Bcl10–Malt1 specifi  cally controls FcεRI-
induced NF-κB activation and the known role of NF-κB 
for cytokine gene expression. Considering all in vitro results 
collectively, we propose a model for the molecular func-
tions of Bcl10 and Malt1 in mast cell signaling that is de-
picted in Fig. 7 C. This signaling model is consistent with 
the in vivo observations in Bcl10- and Malt1-defi  cient mice, 
as immediate phase PCA reactions that depend on mast cell 
degranulation (21) are normal, whereas late phase reactions 
that are at least partially dependent on transcriptional induc-
tion and the release of mast cell–derived cytokines (1, 24) 
are severely impaired in the absence of either Bcl10 or 
Malt1. However, because in the mutant animals all cells lack 
Bcl10 or Malt1, signaling defi  ciencies in other cells besides 
mast cells could additionally contribute to the defective late 
phase PCA response.
Experiments with genetically altered mice have recently 
elucidated many aspects of positive and negative regulation of 
FcεRI-induced mast cell activation (1). Collectively, these 
fi   ndings demonstrate that antigen receptor–specifi  c  mole-
cules required for FcεRI signaling generally aff  ect several as-
pects of mast cell function simultaneously. In contrast, we 
identifi  ed the Bcl10–Malt1 signaling complex as a molecular 
structure that selectively regulates one downstream eff  ector 
arm of FcεRI, namely NF-κB–mediated cytokine produc-
tion, but does not aff  ect mast cell survival, degranulation, or 
the synthesis of leukotrienes.
The conclusion that the Bcl10–Malt1 complex operates 
selectively downstream of PKCs in FcεRI signaling to NF-κB 
Figure 6.  Normal Fc𝗆RI proximal signaling and regular p38, Erk, 
Jnk, and Akt activation in Bcl10−/− and Malt1−/− mast cells. 
(A and B) WT, Bcl10−/−, and Malt1−/− BMMCs sensitized with anti-DNP 
IgE were stimulated with DNP–HSA for the indicated time intervals (in 
minutes) as described in Material and methods. Total cell lysates were 
separated by SDS-PAGE (2 × 105 cell equivalents). (A) Immunoblot 
with anti-phosphotyrosine antibodies. Molecular mass (kD) markers 
are shown on the left. Data are representative of three independent ex-
periments. (B) Immunoblot with anti–phospho-p38, anti–phospho-
p44/42, anti–phospho-Jnk, and anti–phospho-Akt. After stripping, 
membranes were reprobed with anti-p38, anti-p44/p42, anti-Jnk, and 
anti-Akt antibody, respectively. Data are representative of at least three 
independent experiments. (C) Unsensitized WT, Bcl10−/−, and Malt1−/− 
BMMCs were stimulated with PMA/Iono for the indicated time intervals 
(in minutes) as described in Material and methods and immunoblotted as 
in B. Results are representative of three independent experiments.344   REGULATION OF FCεRI SIGNALING BY BCL10 AND MALT1 | Klemm et al.
provides novel insights into context-specifi  c immune regu-
lation. The FcεRI on mast cells belongs to the family of 
multisubunit immunoreceptors that also includes the TCR 
and the B cell receptor (BCR), but numerous genetic stud-
ies have demonstrated that each of these receptors uses 
unique sets of downstream molecules to diff  erentially medi-
ate cell activation. For example, the FcεRI requires the ty-
rosine kinases Syk and Btk and the adaptor molecule linker 
for activation of T cells to mediate mast cell activation (32–
34). Syk and Btk are additionally required for BCR signal-
ing but are completely dispensable for T cell activation, 
whereas the linker for activation of T cells is essential for 
TCR signaling but has no role in B cells (35–37). The 
Bcl10–Malt1 complex is also known to be diff  erentially used 
by immunoreceptors. Bcl10 can bind to Carma molecules 
and recruit Malt1 and various TNF receptor–associated fac-
tor molecules and kinases such as TAK1 into signaling com-
plexes to mediate downstream activation of NF-κB, Jnk, 
and p38 (15, 19, 38–40). TCR signaling to NF-κB critically 
depends on Bcl10, Malt1, and the kinase TAK1 (39). How-
ever, Malt1 is partially expendable for BCR signaling to 
NF-κB (18), and TAK1 is completely dispensable for BCR-
induced NF-κB activation but selectively controls p38 MAP 
kinase signaling in response to BCR ligation (40). Our fi  nd-
ings that FcεRI signaling requires both Bcl10 and Malt1 for 
NF-κB control but not for Jnk or p38 activation extend this 
idea of receptor-specifi  c utilization of the signaling module 
and reinforces the necessity to investigate the precise func-
tion of each signal transducer in distinct cell lineages. So far 
there are no other reports available that explore roles of 
Bcl10, Malt1, or any of their binding partners in FcεRI sig-
naling. It will thus be additionally important to study mast 
cells in mice defi  cient in Carma proteins, TNF receptor–
  associated factor molecules, and MAP kinase–activating ki-
nases, including TAK1, to understand precisely how the 
FcεRI diff  erentially couples to NF-κB and Jnk/p38 down-
stream signaling. These studies could also reveal the Bcl10–
Malt1–independent mechanisms of Jnk and p38 activation 
and give further insights into the selective control of distinct 
mast cell eff  ector functions.
Recent biochemical studies have shown that Bcl10–Malt1 
signaling to IKK and NF-κB involves the oligomerization 
of Bcl10 and Malt1 and subsequent Malt1-dependent regu-
latory lysine-63–linked ubiquitinylation of IKKγ/NEMO, 
Figure 7.  Bcl10 and Malt1 are required for NF-𝗋B signaling in 
mast cells. (A) Defective IκB-α phosphorylation and degradation after 
FcεRI ligation or PMA/Iono treatment in Bcl10−/− or Malt1−/− mast cells. 
BMMCs from all genotypes were sensitized with anti-DNP IgE and stimu-
lated with DNP–HSA for the indicated time intervals (in minutes). Alterna-
tively, cells were left unsensitized and stimulated with PMA/Iono (100 nM 
each). IκB-α phosphorylation and degradation were determined by West-
ern blotting. Membranes were reprobed with anti–β-actin antibody to 
control for equal loading. Data are representative of at least four inde-
pendent experiments. (B) Defective NF-κB activation in Bcl10−/− and 
Malt1−/− mast cells. BMMCs were left unstimulated or stimulated with 
PMA/Iono (100 nM each) for 60 min. Subsequently, nuclear extracts were 
prepared and subjected to gel mobility shift assays using a radiolabeled 
probe containing NF-κB binding site sequences. Results are representa-
tive of three independent experiments. (C) A model for the role of Bcl10 
and Malt1 in FcεRI-mediated signal transduction after FcεRI receptor 
stimulation, Bcl10 and Malt1 operate downstream of PKCs and serve 
as selective signal transducers that activate the IκB-dependent NF-κB 
pathway. The Bcl10–Malt1 complex selectively controls proinfl  ammatory 
cytokine production but does not regulate mast cell degranulation or 
leukotriene synthesis. For details, see Discussion.JEM VOL. 203, February 20, 2006  345
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which induces IKK activity (39, 41). These fi  ndings open 
the   possibility that Bcl10–Malt1 signaling could potentially 
be inhibited by targeted drugs because numerous kinase 
  inhibitors and many compounds that target the ubiquitin/ 
proteasome system are in preclinical or clinical development. 
Mast cell–derived TNF-α recruits and activates neutrophils 
and lymphocytes at sites of infl  ammation and has been impli-
cated in tissue remodeling processes, angiogenesis, and fi  bro-
sis that can be so prominent in IgE-associated chronic allergic 
diseases (1, 23, 42, 43). Consequently, there is a tremendous 
interest in inhibiting TNF-α production in allergic infl  am-
mation. In this paper, we demonstrate that a complete ge-
netic blockage of Bcl10–Malt1 signaling thoroughly abolishes 
FcεRI-specifi  c NF-κB activation and TNF-α and IL-6 pro-
duction in mast cells. Thus, we suggest that specifi  c thera-
peutic targeting of Bcl10–Malt1 signaling could potentially 
contribute to the therapy of mast cell–mediated infl  amma-
tory diseases without the toxic side eff  ects that can be ex-
pected from general NF-κB inhibition.
MATERIALS AND METHODS
Mice. The generation of Bcl10- and Malt1-defi  cient mice was reported 
previously (17, 18). Mice were housed under specifi  c pathogen-free condi-
tions. The study was conducted under federal guidelines for the use and care 
of laboratory animals and was approved by the Government of the District 
of Upper Bavaria. Mice were of a C57BL/6 and 129/J mixed background. 
Littermates were used in each experiment.
Skin histology. Naive animals at 10–12 wk of age were killed, and skin 
samples from the ear, neck, and groin regions were removed and fi  xed in 4% 
formalin. 4-μm tissue sections were stained with toluidine blue, and mast 
cells were counted in the dermis of each sample at 40×. 10 fi  elds at 10× (per 
mouse and location) were used to delineate and integrate the dermal area 
(KS 300 software; Carl Zeiss MicroImaging, Inc.) that was analyzed.
BMMC culture and FACS analysis. Bone marrow cells were cultured in 
suspension in RPMI 1640 with 20% FCS, 30 ng/ml murine IL-3 (R&D 
Systems), 50 ng/ml murine SCF (R&D Systems), and 150 μM monothio-
glycerol (Sigma-Aldrich). To quantify BMMC frequencies, cells were stained 
with FITC-labeled anti-FcεRI and PE-labeled anti–c-kit antibody (eBiosci-
ence) and analyzed by fl  ow cytometry (FACScan; Becton Dickinson).
PCA. For immediate phase PCA reactions, mice were passively sensitized 
by intradermal injection of 250 ng anti-DNP IgE mAb (clone H1-ε-26; 
provided by F.-T. Liu [University of California, Davis, Sacramento, CA] 
and D.H. Katz [Avanir Pharmaceuticals, San Diego, CA]) into one ear and 
PBS injection into the contralateral ear. 24 h later, mice were challenged by 
i.v. injection of 150 μg of DNP–HSA (30–40 moles DNP/mol HSA; 
Sigma-Aldrich) in 100 μl Evans blue dye (0.5%; Sigma-Aldrich). To deter-
mine the amount of extravasated dye, mice were killed, ears were removed, 
and Evans blue dye was extracted with potassium hydroxide and photomet-
rically quantifi  ed as described previously (22).
For late phase PCA reactions, mice were passively sensitized by i.v. 
  injection of 2 μg anti-DNP IgE mAb (clone H1-ε-26) or left unsensitized. 
24 h later, sensitized and nonsensitized mice were challenged by epicutane-
ous application of 10 μl of DNFB (0.2% wt/vol) in acetone/olive oil (4:1) 
to both sides of both ears. The ear swelling response was assessed by measur-
ing the ear thickness using an engineer’s micrometer dial thickness gauge. 
The increment of ear thickness (postchallenge value – prechallenge baseline 
value) was expressed as the percentage of the baseline value obtained before 
antigen challenge.
Mast cell degranulation. To induce degranulation, 2 × 106 BMMCs/ml 
were loaded with 5 μg/ml anti-DNP IgE mAb (SPE-7; Sigma-Aldrich) for 
1 h on ice in Tyrode’s buff  er (10 mM Hepes, pH 7.4, 130 mM NaCl, 5 mM 
KCl, 1.4 mM CaCl2, 1 mM MgCl2, 5.6 mM glucose, and 0.1% BSA). After 
washing, sensitized cells were stimulated with the concentrations of DNP–
HSA indicated in the fi  gures. Alternatively, cells were left unsensitized and 
stimulated with 100 nM PMA (Sigma-Aldrich) and 100 nM Iono (Sigma-
Aldrich) in Tyrode’s buff  er. The enzymatic activities of β-hexosaminidase in 
supernatants and cell pellets solubilized with 0.5% Triton X-100 in Tyrode’s 
Buff   er were measured with p-nitrophenyl-N-acetyl-β-d-glucosaminide 
(Sigma-Aldrich), and the percentage of degranulation was calculated as pre-
viously described (25).
Measurements of leukotrienes and cytokines. 2 × 106 BMMCs/ml 
were loaded with 0.5 μg/ml anti-DNP IgE mAb (SPE-7) overnight, washed 
twice, and stimulated with DNP–HSA or left unsensitized and stimulated 
with PMA and Iono (100 nM each) as indicated in the fi  gures. Cell superna-
tants were harvested, and leukotrienes LTC4, LTD4, and LTE4 were deter-
mined by enzyme-linked immunoassay (GE Healthcare), whereas IL-6 and 
TNF-α were determined by ELISA DuoSets (R&D Systems), as recom-
mended by the manufacturer.
RT-PCR. 2 × 106 BMMCs/ml were loaded with 0.5 μg/ml anti-DNP 
IgE mAb (SPE-7) overnight, washed twice, and stimulated with 20 ng/ml 
DNP–HSA for 30 min. Total RNA was isolated using TRIzol reagent 
  (Invitrogen), according to the manufacturer’s instructions, and reverse tran-
scribed using the Superscript fi  rst-strand synthesis system (Invitrogen). Prim-
ers and PCR conditions were described elsewhere (25).
Survival assay. BMMCs were cultured as indicated in the fi  gures. Cell via-
bility was quantifi  ed by fl  ow cytometry after annexin V/propidium iodide 
staining as recommended by the manufacturer (BD Biosciences).
Signal transduction. For FcεRI signaling, 2 × 106 BMMCs/ml were 
preloaded with 0.5 μg/ml anti-DNP IgE mAb (SPE-7) and subsequently 
activated by adding 20 ng/ml DNP–HSA, as indicated in the fi  gures. Alter-
natively, BMMCs were left unsensitized and stimulated with PMA and 
Iono (100 nM each) or with 5 μg/ml anti-DNP IgE mAb for Bcl-XL in-
duction. Cells were lysed, and denatured proteins were separated on 10% 
polyacrylamide gels and subjected to immunoblotting using antibodies 
against phosphotyrosine (PY99; Santa Cruz Biotechnology, Inc.), phos-
pho-p38, p38, phospho-p44/42, p44/42, phospho-Jnk, Jnk, phospho-Akt, 
Akt, phospho–IκB-α, Iκb-α, Bcl-XL (all from Cell Signaling), or β-actin 
(Sigma-Aldrich). For electromobility shift assays, 107 BMMCs/sample were 
stimulated with PMA/Iono, and gel shifts were performed as described 
previously (17).
Statistical analysis. Results were analyzed for statistical signifi  cance with 
the unpaired two-tailed Student’s t test (Excel; Microsoft). Data from 
Bcl10−/− and Malt1−/− mice or BMMCs were separately compared with the 
WT. Diff  erences between groups were considered signifi  cant at P ≤ 0.05.
We thank Michael Huber and Margot Thome for helpful discussions and advice; 
Frank Redegeld for affi  nity purifying H1-ε-s26 mAb; and Britta Dorn for excellent 
technical assistance.
This work was supported by grants from the German National Genome Project 
(NUWS31T05S15T03, subproject 3b), the German Federal Ministry of Science and 
Education (BMBF 01GC0104, subproject 2), and the Technical University of Munich 
Medical School (KKF 8760179) to T. Jakob and by a Max-Eder-Program grant from 
Deutsche Krebshilfe and grants from the Deutsche Forschungsgemeinschaft (SFB 
455 and SFB 456) to J. Ruland.
The authors have no confl  icting fi  nancial interests.
Submitted: 4 October 2005
Accepted: 23 December 2005346   REGULATION OF FCεRI SIGNALING BY BCL10 AND MALT1 | Klemm et al.
REFERENCES
 1. Galli, S.J., J. Kalesnikoff  , M.A. Grimbaldeston, A.M. Piliponsky, C.M. 
Williams, and M. Tsai. 2005. Mast cells as “tunable” eff  ector  and 
  immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23:
749–786.
  2.  Siraganian, R.P. 2003. Mast cell signal transduction from the high-affi   n-
ity IgE receptor. Curr. Opin. Immunol. 15:639–646.
 3. Rivera, J. 2002. Molecular adapters in Fc(epsilon)RI signaling and the 
allergic response. Curr. Opin. Immunol. 14:688–693.
 4. Kalesnikoff   , J., M. Huber, V. Lam, J.E. Damen, J. Zhang, R.P. 
Siraganian, and G. Krystal. 2001. Monomeric IgE stimulates signaling 
pathways in mast cells that lead to cytokine production and cell survival. 
Immunity. 14:801–811.
  5.  Asai, K., J. Kitaura, Y. Kawakami, N. Yamagata, M. Tsai, D.P. Carbone, 
F.T. Liu, S.J. Galli, and T. Kawakami. 2001. Regulation of mast cell 
survival by IgE. Immunity. 14:791–800.
  6.  Williams, C.M., and S.J. Galli. 2000. The diverse potential eff  ector and 
immunoregulatory roles of mast cells in allergic disease. J. Allergy Clin. 
Immunol. 105:847–859.
 7. Hayden, M.S., and S. Ghosh. 2004. Signaling to NF-kappaB. Genes 
Dev. 18:2195–2224.
 8. Kalesnikoff  , J., N. Baur, M. Leitges, M.R. Hughes, J.E. Damen, M. 
Huber, and G. Krystal. 2002. SHIP negatively regulates IgE + antigen-
induced IL-6 production in mast cells by inhibiting NF-kappa B activ-
ity. J. Immunol. 168:4737–4746.
 9. Azzolina, A., A. Bongiovanni, and N. Lampiasi. 2003. Substance P in-
duces TNF-alpha and IL-6 production through NF kappa B in perito-
neal mast cells. Biochim. Biophys. Acta. 1643:75–83.
10. Jeong, H.J., H.N. Koo, H.J. Na, M.S. Kim, S.H. Hong, J.W. Eom, 
K.S. Kim, T.Y. Shin, and H.M. Kim. 2002. Inhibition of TNF-alpha 
and IL-6 production by Aucubin through blockade of NF-kappaB 
  activation RBL-2H3 mast cells. Cytokine. 18:252–259.
11. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiqui-
tination: the control of NF-κB activity. Annu. Rev. Immunol. 18:
621–663.
12. Lorentz, A., I. Klopp, T. Gebhardt, M.P. Manns, and S.C. Bischoff  . 
2003. Role of activator protein 1, nuclear factor-kappaB, and nuclear 
factor of activated T cells in IgE receptor-mediated cytokine expres-
sion in mature human mast cells. J. Allergy Clin. Immunol. 111:
1062–1068.
13.  Marquardt, D.L., and L.L. Walker. 2000. Dependence of mast cell IgE-
mediated cytokine production on nuclear factor-kappaB activity.
 J. Allergy Clin. Immunol. 105:500–505.
14. Peng, Y., M.R. Power, B. Li, and T.J. Lin. 2005. Inhibition of IKK 
down-regulates antigen + IgE-induced TNF production by mast cells: 
a role for the IKK-IκB-NF-κB pathway in IgE-dependent mast cell 
  activation. J. Leukoc. Biol. 77:975–983.
15. Thome, M. 2004. CARMA1, BCL-10 and MALT1 in lymphocyte 
development and activation. Nat. Rev. Immunol. 4:348–359.
16. Ruefl  i-Brasse, A.A., D.M. French, and V.M. Dixit. 2003. Regulation 
of NF-kappaB-dependent lymphocyte activation and development by 
paracaspase. Science. 302:1581–1584.
17. Ruland, J., G.S. Duncan, A. Elia, I. del Barco Barrantes, L. Nguyen, 
S. Plyte, D.G. Millar, D. Bouchard, A. Wakeham, P.S. Ohashi, and 
T.W. Mak. 2001. Bcl10 is a positive regulator of antigen receptor-
  induced activation of NF-kappaB and neural tube closure. Cell. 104:
33–42.
18. Ruland, J., G.S. Duncan, A. Wakeham, and T.W. Mak. 2003. 
Diff  erential requirement for Malt1 in T and B cell antigen receptor sig-
naling. Immunity. 19:749–758.
19. Thome, M., O. Gaide, O. Micheau, F. Martinon, D. Bonnet, M. 
Gonzalez, and J. Tschopp. 2001. Equine herpesvirus protein E10 in-
duces membrane recruitment and phosphorylation of its cellular homo-
logue, bcl-10. J. Cell Biol. 152:1115–1122.
20. Xue, L., S.W. Morris, C. Orihuela, E. Tuomanen, X. Cui, R. Wen, 
and D. Wang. 2003. Defective development and function of Bcl10-
  defi   cient follicular, marginal zone and B1 B cells. Nat. Immunol. 4:
857–865.
21. Inagaki, N., S. Goto, H. Nagai, and A. Koda. 1986. Homologous pas-
sive cutaneous anaphylaxis in various strains of mice. Int. Arch. Allergy 
Appl. Immunol. 81:58–62.
22. Nagai, H., T. Sakurai, N. Inagaki, and H. Mori. 1995. An immuno-
pharmacological study of the biphasic allergic skin reaction in mice. 
Biol. Pharm. Bull. 18:239–245.
23.  Nakae, S., H. Suto, M. Kakurai, J.D. Sedgwick, M. Tsai, and S.J. Galli. 
2005. Mast cells enhance T cell activation: importance of mast cell-
  derived TNF. Proc. Natl. Acad. Sci. USA. 102:6467–6472.
24.  Wershil, B.K., Z.S. Wang, J.R. Gordon, and S.J. Galli. 1991. 
Recruitment of neutrophils during IgE-dependent cutaneous late phase 
reactions in the mouse is mast cell-dependent. Partial inhibition of 
the reaction with antiserum against tumor necrosis factor-alpha. J. Clin. 
Invest. 87:446–453.
25. Nishizumi, H., and T. Yamamoto. 1997. Impaired tyrosine phos-
phorylation and Ca2+ mobilization, but not degranulation, in 
lyn-defi   cient bone marrow-derived mast cells. J. Immunol. 158:
2350–2355.
26.  Tan, S.L., and P.J. Parker. 2003. Emerging and diverse roles of protein 
kinase C in immune cell signaling. Biochem. J. 376:545–552.
27. Abdel-Raheem, I.T., I. Hide, Y. Yanase, Y. Shigemoto-Mogami, N. 
Sakai, Y. Shirai, N. Saito, F.M. Hamada, N.A. El-Mahdy, D. Elsisy Ael, 
et al. 2005. Protein kinase C-alpha mediates TNF release process in 
RBL-2H3 mast cells. Br. J. Pharmacol. 145:415–423.
28.  Kawakami, Y., J. Kitaura, S.E. Hartman, C.A. Lowell, R.P. Siraganian, 
and T. Kawakami. 2000. Regulation of protein kinase CbetaI by two 
protein-tyrosine kinases, Btk and Syk. Proc. Natl. Acad. Sci. USA. 97:
7423–7428.
29. Nechushtan, H., M. Leitges, C. Cohen, G. Kay, and E. Razin. 2000. 
Inhibition of degranulation and interleukin-6 production in mast 
cells derived from mice defi  cient in protein kinase Cbeta. Blood. 95:
1752–1757.
30.  Cho, S.H., C.H. Woo, S.B. Yoon, and J.H. Kim. 2004. Protein kinase 
Cdelta functions downstream of Ca2+ mobilization in FcepsilonRI 
  signaling to degranulation in mast cells. J. Allergy Clin. Immunol. 
114:1085–1092.
31. Leitges, M., K. Gimborn, W. Elis, J. Kalesnikoff  , M.R. Hughes, G. 
Krystal, and M. Huber. 2002. Protein kinase C-delta is a negative regu-
lator of antigen-induced mast cell degranulation. Mol. Cell. Biol. 22:
3970–3980.
32. Costello, P.S., M. Turner, A.E. Walters, C.N. Cunningham, P.H. 
Bauer, J. Downward, and V.L. Tybulewicz. 1996. Critical role for the 
tyrosine kinase Syk in signalling through the high affi   nity IgE receptor 
of mast cells. Oncogene. 13:2595–2605.
33. Hata, D., Y. Kawakami, N. Inagaki, C.S. Lantz, T. Kitamura, W.N. 
Khan, M. Maeda-Yamamoto, T. Miura, W. Han, S.E. Hartman, et al. 
1998. Involvement of Bruton’s tyrosine kinase in FcεRI-dependent 
mast cell degranulation and cytokine production. J. Exp. Med. 187:
1235–1247.
34.  Saitoh, S., R. Arudchandran, T.S. Manetz, W. Zhang, C.L. Sommers, 
P.E. Love, J. Rivera, and L.E. Samelson. 2000. LAT is essential for 
FcεRI-mediated mast cell activation. Immunity. 12:525–535.
35. Khan, W.N., F.W. Alt, R.M. Gerstein, B.A. Malynn, I. Larsson, G. 
Rathbun, L. Davidson, S. Muller, A.B. Kantor, L.A. Herzenberg, et al. 
1995. Defective B cell development and function in Btk-defi  cient mice. 
Immunity. 3:283–299.
36. Turner, M., P.J. Mee, P.S. Costello, O. Williams, A.A. Price, L.P. 
Duddy, M.T. Furlong, R.L. Geahlen, and V.L. Tybulewicz. 1995. 
Perinatal lethality and blocked B-cell development in mice lacking the 
tyrosine kinase Syk. Nature. 378:298–302.
37. Zhang, W., C.L. Sommers, D.N. Burshtyn, C.C. Stebbins, J.B. 
DeJarnette, R.P. Trible, A. Grinberg, H.C. Tsay, H.M. Jacobs, C.M. 
Kessler, et al. 1999. Essential role of LAT in T cell development. 
Immunity. 10:323–332.
38.  Thome, M., F. Martinon, K. Hofmann, V. Rubio, V. Steiner, P. Schneider, 
C. Mattmann, and J. Tschopp. 1999. Equine herpesvirus-2 E10 gene 
  product, but not its cellular homologue, activates NF-kappaB transcrip-
tion factor and c-Jun N-terminal kinase. J. Biol. Chem. 274:9962–9968.JEM VOL. 203, February 20, 2006  347
ARTICLE
39.  Sun, L., L. Deng, C.K. Ea, Z.P. Xia, and Z.J. Chen. 2004. The TRAF6 
ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 
and MALT1 in T lymphocytes. Mol. Cell. 14:289–301.
40. Sato, S., H. Sanjo, K. Takeda, J. Ninomiya-Tsuji, M. Yamamoto, T. 
Kawai, K. Matsumoto, O. Takeuchi, and S. Akira. 2005. Essential func-
tion for the kinase TAK1 in innate and adaptive immune responses. Nat. 
Immunol. 6:1087–1095.
41.  Zhou, H., I. Wertz, K. O’Rourke, M. Ultsch, S. Seshagiri, M. Eby, W. 
Xiao, and V.M. Dixit. 2004. Bcl10 activates the NF-kappaB pathway 
through ubiquitination of NEMO. Nature. 427:167–171.
42. Biedermann, T., M. Kneilling, R. Mailhammer, K. Maier, C.A. 
Sander, G. Kollias, S.L. Kunkel, L. Hultner, and M. Rocken. 2000. 
Mast cells control neutrophil recruitment during T cell–mediated 
  delayed-type hypersensitivity reactions through tumor necrosis factor 
and macrophage infl   ammatory protein 2. J. Exp. Med. 192:
1441–1452.
43. McLachlan, J.B., J.P. Hart, S.V. Pizzo, C.P. Shelburne, H.F. Staats, 
M.D. Gunn, and S.N. Abraham. 2003. Mast cell-derived tumor necrosis 
factor induces hypertrophy of draining lymph nodes during infection. 
Nat. Immunol. 4:1199–1205.